Employees: 900
Size Katakura Industries (3001.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $765M, the 860th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,710 on 18 Nov 2026.
Performance Over six months the shares gained 39.6%, against -7.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue fell 1.5% over the last twelve months (peer median +3.5%); the operating margin is 15.5% (peer median 10.4%).
Valuation It trades at 2.4× enterprise value to sales against a peer median of 2.5× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.5 points above its cost of capital (5.0% WACC).
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥40.4B | ¥40.7B | ¥39.4B | ¥40.0B | ¥34.3B |
| Revenue growth | — | +3% | -1% | +17% | — |
| Gross profit | ¥15.0B | ¥14.4B | ¥14.5B | ¥15.1B | ¥12.6B |
| EBITDA | ¥9.27B | ¥8.76B | ¥6.95B | ¥6.46B | ¥4.05B |
| Net income | ¥7.34B | ¥5.76B | ¥3.52B | ¥3.04B | ¥2.82B |
| Free cash flow | n/a | ¥5.66B | ¥3.65B | ¥2.50B | -¥1.70B |
| Capital expenditure | n/a | ¥2.67B | ¥2.06B | ¥1.11B | ¥1.05B |
| Total debt | ¥6.12B | ¥8.95B | ¥11.0B | ¥12.6B | ¥14.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3001.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.6% | -6.5% | 2nd highest of 19 |
| 6-month return | +39.6% | -7.5% | 4th highest of 19 |
| Distance from 52-week high | -10.2% | -34.0% | 3rd highest of 19 |
| Revenue growth (TTM) | -1.5% | +3.5% | 6th lowest of 19 |
| Operating margin | 15.5% | 10.4% | 8th highest of 19 |
| EV / Sales | 2.4× | 2.5× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 0.3% | 4.0% | 6th least demanding of 13 |
| Growth delivered (Del g) | +0.5% | +2.3% | 6th lowest of 13 |
| Hurdle (Req g minus delivered) | -0.2 pp | -4.1 pp | 5th most demanding of 13 |
| ROIC minus cost of capital | +0.5 pp | +1.9 pp | 9th lowest of 18 |
| EV / EBITDA | 10.4× | 10.0× | 4th cheapest of 7 |
| Net debt / EBITDA | -2.9× | -0.5× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | 2.5× | 13.5% | -0.2% |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | 5.3× | 9.4% | -1.4% |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | 0.3× | n/a | n/a |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 1.6× | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | 1.4× | -2.1% | 0.0% |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | 3.1× | -2.5% | +2.6% |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 1.8× | -2.0% | +26.1% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 1.1× | -11.8% | +1.9% |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |